ReviewJournal of thoracic disease2015
Anticoagulation management in mechanical circulatory support.
Review in Journal of thoracic disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025Article
- Observational
- Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy.Journal of anatomy · 2023Review
- Gastrointestinal Bleeding as a Complication in Continuous Flow Ventricular Assist Devices: A Systematic Review With Meta-Analysis.Journal of clinical medicine research · 2020Article
- Post-operative of bleeding, haemolysis and coagulation in mechanical circulatory support patients.Annals of translational medicine · 2020Review
- Low immunogenic endothelial cells endothelialize the Left Ventricular Assist Device.Scientific reports · 2019Article
- Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding.Artificial organs · 2019Article
- Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2019Observational
- An introduction to point-of-care testing in extracorporeal circulation and LVADs.Hematology. American Society of Hematology. Education Program · 2018Review
- Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-SpecificTheranostics · 2018Article
- Anticoagulation management following left ventricular assist device implantation is similar across all provider strategies.Interactive cardiovascular and thoracic surgery · 2018Article
- New Challenges in the Treatment of Patients With Left Ventricular Support: LVAD Thrombosis.Current heart failure reports · 2016Review
- Facilitating noncardiac surgery for the patient with left ventricular assist device: A guide for the anesthesiologist.Annals of cardiac anaesthesiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure continues to be a worldwide epidemic, effecting over 23 million persons. Despite advances in medical therapy, the disease is progressive and a significant proportion of patients will need advanced heart replacement therapy. Continuous flow assist devices have become a standard approach for many patients both as a bridge to cardiac transplantation and as destination therapy (DT). However, device related complications such as bleeding and thrombosis continue to hinder further advancements of this technology. The field is rapidly advancing and efforts to reduce pump complications are directed towards improving hemocompatibility and maximizing blood flow without clinically significant hemolysis, areas of stasis or turbulent flow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.